home / stock / xphyf / xphyf news

XPHYF News and Press, XPhyto Therapeutics Corp From 04/12/22

Stock Information
Company Name: XPhyto Therapeutics Corp
Stock Symbol: XPHYF
Market: OTC
Menu
XPHYF XPHYF Quote XPHYF Short XPHYF News XPHYF Articles XPHYF Message Board
Get XPHYF Alerts

News, Short Squeeze, Breakout and More Instantly...
XPHYF - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Market, Product Development of Key Biosensor

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released a market and product development report. The report focused on XPhyto’s sublingual oral dissolvable film ("ODF") biosensor developm...
XPHYF - XPhyto, Biosensors Market and Product Developments on Platform-Based Oral Dissolvable Biosensors for Oral Health and Infectious Disease

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / April 11, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Sublingual oral dissolvable film ("ODF") biosensor development ...

XPHYF - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Update on Rotigotine Transdermal Patch Development

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, is reporting on the market and product development of its Rotigotine transdermal ("TDS") patch, which is designed for the treatment of Parkinson's dise...

XPHYF - XPhyto Reports Market and Product Developments on Platform-based Rotigotine Transdermal Patch for Parkinson's Disease

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / April 4, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Rotigotine transdermal ("TDS") patch. The Company's Rotigotine...
XPHYF - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Closes First Tranche of Private Placement

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that, further to its news release of March 25, 2022, it has closed the f...

XPHYF - XPhyto Closes First Tranche of Financing

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / March 31, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that further to its news release of March 25, 2022, it has closed the first tranche of its private placem...

XPHYF - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Updates on Psychedelic Medicine Programs Progess, Novel Compounds Milestone

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, has released an update regarding its wholly owned subsidiary XPhyto Laboratories Inc. XPhyto Labs' psychedelic medicine programs are focused on a multi...
XPHYF - XPhyto Provides Progress Update on Psychedelic Medicine Programs and Novel Compounds Milestone

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / February 22, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on its wholly owned subsidiary XPhyto Laboratories Inc. ("XPhyto Labs"). XPhyto Labs' psychedelic...

XPHYF - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update Regarding Its Three Primary Business Divisions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today issued an update as part of its product development, commercialization and reven...

XPHYF - XPhyto Reports on its Three Primary Business Divisions

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / February 8, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to report on its three business divisions as part of its product development, commercialization, and revenue growth str...
Previous 10 Next 10